DoseMe has acquired Firstline, creating a single path from therapy choice to personalised dosing so clinicians can reach optimal care faster.
Financial terms were not disclosed. Jupiter, Florida-based DoseMe is a portfolio company of Fairlong Capital. Firstline, based in Vancouver, Canada, provides clinical decision support used by healthcare organisations worldwide.
Firstline’s mobile-first software makes infectious disease protocols easy to access and uses local resistance data to help cut antibiotic overuse and improve stewardship.
DoseMe’s model-informed precision dosing software tailors doses using clinically validated PK/PD models, patient characteristics, measured drug concentrations and, when available, genotype. PK/PD links how the body handles a drug (pharmacokinetics) with the drug’s effects (pharmacodynamics).
The platform is HIPAA compliant and, according to the company, the only Bayesian dosing system with both HITRUST CSF R2 and ISO 13485 certification. Bayesian dosing updates recommendations by combining prior knowledge with each patient’s latest results.
DoseMe is led by chief executive Paul Edwards.
